GW Pharma cannabinoid to be tested for Alzheimer's agitation; Acorda revenue plummets as generics eviscerate its franchise
→ Alzheimer’s Research UK is funding a study at King’s College using GW Pharma’s recently approved cannabinoid drug Sativex in dementia. The study will focus on Alzheimer’s patients exhibiting signs of aggression and agitation.
→ Now that Eli Lilly has acquired Loxo in an $8 billion buyout, Loxo partner Bayer is going its own way on a pair of programs. The pharma company reported Friday morning that it obtained full rights for Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) under their change-of-control clause. Bayer now has exclusive marketing rights in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.